Cytek Biosciences, Inc. CTKB

Brown Capital Management, an investment management company, released its second-quarter 2026 investor letter for “The Brown Capital Management Small Company Fund.” The letter can be downloaded here. For the quarter ended June 30, 2026, market volatility reflected uncertainty around AI spending and Middle East tensions. The Magnificent Seven fell more than 8% in June, while […]

Industry’s First End-to-End Flow Cytometry Platform Covering Panel Design Through Data Analysis Cytek® Cloud digital ecosystem Cytek® Biosciences has expanded its Cytek® Cloud digital ecosystem with a new Cloud Analysis tool, establishing the industry’s first end-to-end platform that integrates the entire flow cytometry workflow, from panel design to data analysis, into one system. FREMONT, Calif., Sept. 23, 2026 (GLOBE NEWSWIRE) -- Spectral flow cytometry leader Cytek Biosciences, Inc. (Nasdaq:

Complementary Technologies Deliver an Integrated, End-to-End Clinical Flow Cytometry Workflow for Laboratories Across Europe Cytek Biosciences and Sysmex Europe Collaborate Cytek Biosciences and Sysmex Europe have signed an agreement establishing a strategic collaboration to enhance clinical flow cytometry workflows and expand access to innovative diagnostic solutions. By combining their complementary technologies, the collaboration will provide an integrated, end-to-end clinical flow cytometry

On August 5, Cytek Biosciences (NASDAQ:CTKB) reported financial results for the second quarter ended June 30, and the report reads like two different companies at once. Revenue climbed, margins widened, and the installed base of instruments kept expanding. At the same time, the net loss more than doubled from a year earlier and adjusted EBITDA […]

FREMONT, Calif., Sept. 03, 2026 (GLOBE NEWSWIRE) -- As clinical laboratories seek deeper cellular insights, greater efficiency, and more streamlined approaches to cell analysis, spectral flow cytometry leader Cytek Biosciences, Inc. (Nasdaq: CTKB) will showcase its advanced solutions at two leading clinical cytometry events this fall: the European Society for Clinical Cell Analysis (ESCCA) 2026 Conference and ICCS 2026, the 41st Annual International Clinical Cytometry Meeting & Course. Set apart

FREMONT, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, today announced the company will be participating in the following investor conferences.Wells Fargo 21st Annual Healthcare Conference in Boston, MACFO William McCombe will be participating in investor meetings on Tuesday, September 8, 2026Morgan Stanley 24th Annual Global Healthcare Conference in New York, NYCEO Wenbin Jiang and CFO William McCombe will be partic

FREMONT, Calif., Aug. 21, 2026 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (“Cytek Biosciences,” “Cytek,” or the “Company”) (Nasdaq: CTKB), a leading cell analysis solutions company, today announced that a jury in the United States District Court for the District of Delaware returned a verdict in the patent infringement action brought by Beckman Coulter, Inc. The jury found in Cytek’s favor on three of the four asserted patent claims, finding noninfringement and invalidity as to each of those th

Moby summary of Cytek Biosciences, Inc.'s Q2 2026 earnings call

Cytek Biosciences Inc (CTKB) delivers solid Q2 2026 results with 6% revenue growth, launches the industry-first Borealis 60-color system, and raises full-year guidance despite EMEA softness.

FREMONT, Calif., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), a leading cell analysis solutions company, today reported financial results for the second quarter ended June 30, 2026. Recent Highlights Total revenue for the second quarter of 2026 was $48.1 million, representing a 6% increase compared to the second quarter of 2025Launched Cytek Borealis™, a new 7-laser full spectrum flow cytometer with new and proprietary reagents enabli

FREMONT, Calif., July 22, 2026 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), today announced that it will report financial results for the second quarter of 2026 after market close on Wednesday, August 5, 2026. The company’s management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its results, business developments and outlook. Live audio of the webcast will be available on the “